Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1130525

registered interest
date	06/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Doctors: Pensions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has conducted of the effect of the tapered annual pension tax allowance on the retention of doctors in the NHS.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	261238
answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>The 2015 NHS Pension Scheme is a generous and valuable part of staff reward packages and remains one of the best schemes available. Its introduction ensures that National Health Service staff receive financial security in retirement, and that the scheme is affordable to the taxpayer.</p><p>The Government recognises that NHS doctors have raised concerns about pension tax charges being a factor in their decisions to retire early or limit their NHS commitments.</p><p>We are listening to concerns raised that the tapered annual allowance is affecting the retention of doctors in the NHS. The Government is prepared to take action and will bring forward a public consultation on targeted proposals to make NHS pensions more flexible for senior clinicians by allowing them a 50% reduction in pension contributions for half the pension accrual.</p><p>The British Medical Association’s view this proposal as a step in the right direction. The Department will listen carefully during consultation to reach a final proposition that works for both staff and taxpayers. The consultation gives an opportunity for groups and individuals to put forward their views.</p><p>Additionally, the scope of the voluntary ‘Scheme Pays’ facility, implemented by the NHS Pension Scheme to allow scheme members to pay annual allowance charges from the value of their pension benefits rather than upfront, has been extended to cover the payment of tax charges from breaches of the tapered annual allowance. The Government keeps the impact of public sector pay and pensions policies under constant review.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 11/06/2019 15:46:09 answering member 1585 label Biography information for Stephen Hammond
tabling member	4385 label Biography information for Dr Philippa Whitford

1110235

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with community (a) pharmacies and (b) pharmacy organisations in Scotland on the implementation of the Human Medicines (Amendment) Regulations 2019 (S.I., 2019, No. 62).
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	242153
answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>Community Pharmacy Scotland is a member of the joint Departmental and Medicines and Healthcare products Regulatory Agency Falsified Medicines Directive Implementation Advisory Board. In relation to implementation of the serious shortage protocol provisions the Department has had discussions with Community Pharmacy Scotland, representing community pharmacy owners in Scotland, in the Pharmaceutical Services Negotiating Committee Brexit Forum.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/04/2019 16:59:00 answering member 4455 label Biography information for Seema Kennedy
tabling member	4385 label Biography information for Dr Philippa Whitford

1110241

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Scottish Government’s Chief Pharmaceutical Officer on the implementation of legislative changes in the Human Medicines (Amendment) Regulations 2019 (S.I., 2019, No. 62).
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	242154
answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>The Department has engaged fully with officials of the Scottish Government, including its Chief Pharmaceutical Officer, on the implementation of legislative changes in the Human Medicines (Amendment) Regulations 2019 (S.I. 2019, No. 62) in relation to the Falsified Medicines Directive and the Serious Shortage Protocol.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/04/2019 16:57:37 answering member 4455 label Biography information for Seema Kennedy
tabling member	4385 label Biography information for Dr Philippa Whitford

1110245

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with Scotland’s Cabinet Secretary for Health and Sport on the stockpiling of drugs in preparation for the UK’s departure from the EU.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	242155
answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care regularly discusses ‘no deal’ contingency plans, including those relating to the supply of medicines and medical products, with a number of stakeholders, the National Health Service and other Government Departments. Furthermore, I engage with Ministerial counterparts in both the Welsh and Scottish Governments, as well as the Permanent Secretary for the Department of Health in the Northern Ireland Civil Service, on European Union exit ‘no deal’ preparations.</p><p> </p><p>The Department has overall responsibility to ensure the continuity of supply of medicines and medical products for the whole of the United Kingdom; close engagement and cooperation with colleagues in the devolved administrations reflects this.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 242156 242157 question first answered 11/04/2019 16:09:07 answering member 1585 label Biography information for Stephen Hammond
tabling member	4385 label Biography information for Dr Philippa Whitford

1110280

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with Scotland’s Cabinet Secretary for Health and Sport on what processes will be in place to add a drug to the list of those deemed to be in short supply following the UK’s departure from the EU.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	242156
answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care regularly discusses ‘no deal’ contingency plans, including those relating to the supply of medicines and medical products, with a number of stakeholders, the National Health Service and other Government Departments. Furthermore, I engage with Ministerial counterparts in both the Welsh and Scottish Governments, as well as the Permanent Secretary for the Department of Health in the Northern Ireland Civil Service, on European Union exit ‘no deal’ preparations.</p><p> </p><p>The Department has overall responsibility to ensure the continuity of supply of medicines and medical products for the whole of the United Kingdom; close engagement and cooperation with colleagues in the devolved administrations reflects this.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 242155 242157 question first answered 11/04/2019 16:09:07 answering member 1585 label Biography information for Stephen Hammond
tabling member	4385 label Biography information for Dr Philippa Whitford

1110326

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radioisotopes: Scotland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with Scotland’s Cabinet Secretary for Health and Sport on the security of the supply of radioisotopes to Scottish hospitals after the UK has left the EU.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	242157
answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care regularly discusses ‘no deal’ contingency plans, including those relating to the supply of medicines and medical products, with a number of stakeholders, the National Health Service and other Government Departments. Furthermore, I engage with Ministerial counterparts in both the Welsh and Scottish Governments, as well as the Permanent Secretary for the Department of Health in the Northern Ireland Civil Service, on European Union exit ‘no deal’ preparations.</p><p> </p><p>The Department has overall responsibility to ensure the continuity of supply of medicines and medical products for the whole of the United Kingdom; close engagement and cooperation with colleagues in the devolved administrations reflects this.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 242155 242156 question first answered 11/04/2019 16:09:07 answering member 1585 label Biography information for Stephen Hammond
tabling member	4385 label Biography information for Dr Philippa Whitford

1110330

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Reciprocal Arrangements
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with Scotland’s Cabinet Secretary for Health and Sport on how existing reciprocal healthcare arrangements for people from the (a) UK, (b) EU, and (c) European Economic Area will be affected by the UK leaving the EU.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	242158
answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care regularly discusses plans for European Union exit, including those relating to reciprocal healthcare, with a wide range of stakeholders and other Government Departments.</p><p>Furthermore, I engage with Ministerial counterparts in both the Welsh and Scottish Governments, as well as the Permanent Secretary for the Department of Health in the Northern Ireland Civil Service, on preparations for EU exit.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 11/04/2019 16:07:02 answering member 1585 label Biography information for Stephen Hammond
tabling member	4385 label Biography information for Dr Philippa Whitford

1091126

registered interest
date	19/03/2019
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Public Interest Disclosure Act 1998
house id	1
legislature	25259 pref label House of Commons
question text	What plans he has to review the operation of the Public Interest Disclosure Act 1998.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	909885
answer	answer is ministerial correction date of answer 19/03/2019 answer text <p>The Government has continued to examine and make reforms to the whistleblowing regime, both to the guidance and legislative framework of protections for workers. The most recent reforms came into effect last year.</p><p> </p><p>The Government will continue to listen to stakeholders and will, of course, review the recent reforms once there is sufficient evidence of their impact.</p> answering member constituency Rochester and Strood answering member printed Kelly Tolhurst question first answered 19/03/2019 15:16:28 answering member 4487 label Biography information for Kelly Tolhurst
tabling member	4385 label Biography information for Dr Philippa Whitford

1082133

registered interest
date	05/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Tackling Antimicrobial Resistance Action Plan 2019-2024, how delinking the price paid for antimicrobials from the volume sold will ensure that products produced by industry are affordable to the NHS.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	228682
answer	answer is ministerial correction date of answer 11/03/2019 answer text <p>The 2016 United Nations political declaration on antimicrobial resistance (AMR) acknowledged the importance of delinking the cost of investment in research and development on AMR from the price and volume of sales to facilitate equitable and affordable access to new products and encouraged governments to explore innovative approaches.</p><p> </p><p>It is critical that the National Health Service makes the best use of its resources. Any payment model must therefore be based on a robust evaluation of the value that a new antimicrobial product brings to patients and the public as a whole. The assessment of how much value a new antibiotic brings is highly complex and will vary considerably from one product to another.</p><p> </p><p>In the United Kingdom, NHS England and the National Institute for Health and Care Excellence (NICE) are leading work to test innovative models that pay companies based primarily on a NICE led health technology assessment of their value to the NHS as opposed to the volumes used. This has the potential to both promote good antimicrobial stewardship and provide a much-needed incentive for the development of new antimicrobial agents that will, over time, provide value for the NHS.</p><p> </p><p>The test will be subject to robust evaluation before considering any wider change to purchasing policy. The UK represents only a small part of the global market for these drugs and we want to send a signal to the rest of the world that there are workable models to achieve the right sort of incentives for these vital medicines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 228683 question first answered 11/03/2019 18:32:38 answering member 4067 label Biography information for Steve Brine previous answer version 106924 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1082134

registered interest
date	05/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using models that de-link the cost of research and development from the price of the final product and the volume of sales, as set out in the 2016 UN Political Declaration of the High-Level Meeting of the General Assembly on antimicrobial resistance, to ensure that new diagnostics, medicines and tools created are accessible and affordable.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	228683
answer	answer is ministerial correction date of answer 11/03/2019 answer text <p>The 2016 United Nations political declaration on antimicrobial resistance (AMR) acknowledged the importance of delinking the cost of investment in research and development on AMR from the price and volume of sales to facilitate equitable and affordable access to new products and encouraged governments to explore innovative approaches.</p><p> </p><p>It is critical that the National Health Service makes the best use of its resources. Any payment model must therefore be based on a robust evaluation of the value that a new antimicrobial product brings to patients and the public as a whole. The assessment of how much value a new antibiotic brings is highly complex and will vary considerably from one product to another.</p><p> </p><p>In the United Kingdom, NHS England and the National Institute for Health and Care Excellence (NICE) are leading work to test innovative models that pay companies based primarily on a NICE led health technology assessment of their value to the NHS as opposed to the volumes used. This has the potential to both promote good antimicrobial stewardship and provide a much-needed incentive for the development of new antimicrobial agents that will, over time, provide value for the NHS.</p><p> </p><p>The test will be subject to robust evaluation before considering any wider change to purchasing policy. The UK represents only a small part of the global market for these drugs and we want to send a signal to the rest of the world that there are workable models to achieve the right sort of incentives for these vital medicines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 228682 question first answered 11/03/2019 18:32:38 answering member 4067 label Biography information for Steve Brine previous answer version 106925 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford